Lymphoma Patients' vaccine shield under microscope
NCT ID NCT05050461
Summary
This study aimed to understand how well COVID-19 vaccines protect adults with B-cell non-Hodgkin lymphoma, especially those taking a common treatment called anti-CD20 therapy. Researchers compared the immune responses (antibodies and T-cells) in vaccinated lymphoma patients who had recently received this treatment versus those who had not. The goal was to gather knowledge to help guide future vaccine recommendations for this vulnerable group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA,B CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
André Mignot -Versailles Hospital, Hemato-oncology unit
Le Chesnay, Île-de-France Region, 78150, France
-
Emile Muller Hospital, Hematology unit
Mulhouse, 68100, France
-
Hospitals of Brabois, Hematology unit
Vandœuvre-lès-Nancy, 54500, France
-
Institut of Cancerology Strasbourg Europe (ICANS), Hematology deparment
Strasbourg, 67000, France
-
Pitié Salpêtrière Hospital, Hematology unit
Paris, Île-de-France Region, 75013, France
-
Saint Antoine Hospital, Hematology unit
Paris, Île-de-France Region, 75012, France
-
saint Louis Hospital, Hemato-oncology unit
Paris, Île-de-France Region, 75010, France
Conditions
Explore the condition pages connected to this study.